AKL Therapeutics

AKL Therapeutics is a privately held UK pharmaceutical company developing APPA, a patented oral investigational medicine combining two synthetic plant metabolites that act synergistically to target multiple signalling pathways in osteoarthritis. Animal studies have demonstrated pain reduction and delayed cartilage degradation.

APPA has completed a Phase II trial and is preparing to enter a Phase IIb study at higher doses. Recent research has also identified senolytic and senomorphic properties, expanding its potential into age-related conditions.